메뉴 건너뛰기




Volumn 127, Issue 25, 2013, Pages 2485-2493

High-dose statin therapy in patients with stable coronary artery disease: Treating the right patients based on individualized prediction of treatment effect

Author keywords

coronary disease; forecasting; prevention and control; statins, HMG CoA; treatment outcome

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

EID: 84879515288     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000712     Document Type: Article
Times cited : (34)

References (33)
  • 2
    • 27744603499 scopus 로고    scopus 로고
    • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial
    • Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
    • Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
    • (2005) JAMA , vol.294 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3    Olsson, A.G.4    Tikkanen, M.J.5    Holme, I.6    Larsen, M.L.7    Bendiksen, F.S.8    Lindahl, C.9    Szarek, M.10    Tsai, J.11
  • 3
    • 78449267756 scopus 로고    scopus 로고
    • Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial
    • Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658-1669.
    • (2010) Lancet , vol.376 , pp. 1658-1669
    • Armitage, J.1    Bowman, L.2    Wallendszus, K.3    Bulbulia, R.4    Rahimi, K.5    Haynes, R.6    Parish, S.7    Peto, R.8    Collins, R.9
  • 4
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
    • Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3    Rader, D.J.4    Rouleau, J.L.5    Belder, R.6    Joyal, S.V.7    Hill, K.A.8    Pfeffer, M.A.9    Skene, A.M.10
  • 10
    • 33748303084 scopus 로고    scopus 로고
    • Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study
    • Treating to New Targets Investigators
    • Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-928.
    • (2006) Lancet , vol.368 , pp. 919-928
    • Deedwania, P.1    Barter, P.2    Carmena, R.3    Fruchart, J.C.4    Grundy, S.M.5    Haffner, S.6    Kastelein, J.J.7    Larosa, J.C.8    Schachner, H.9    Shepherd, J.10    Waters, D.D.11
  • 11
    • 0346962889 scopus 로고    scopus 로고
    • Treating to New Targets (TNT) study does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit
    • TNT Steering Committee Members and Investigators
    • Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004;93:154-158.
    • (2004) Am J Cardiol , vol.93 , pp. 154-158
    • Waters, D.D.1    Guyton, J.R.2    Herrington, D.M.3    McGowan, M.P.4    Wenger, N.K.5    Shear, C.6
  • 12
    • 4544223864 scopus 로고    scopus 로고
    • Design and baseline characteristics of the incremental decrease in end points through aggressive lipid lowering study
    • Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group
    • Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. Am J Cardiol. 2004;94:720-724.
    • (2004) Am J Cardiol , vol.94 , pp. 720-724
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3    Olsson, A.G.4    Tikkanen, M.J.5    Holme, I.6    Larsen, M.L.7    Bendiksen, F.S.8    Lindahl, C.9    Palmer, G.10
  • 16
    • 0036176161 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
    • K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
    • (2002) Am J Kidney Dis , vol.39
  • 18
    • 0030069896 scopus 로고    scopus 로고
    • Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
    • Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
    • (1996) Stat Med , vol.15 , pp. 361-387
    • Harrell Jr., F.E.1    Lee, K.L.2    Mark, D.B.3
  • 20
    • 0642279547 scopus 로고    scopus 로고
    • A method for checking regression models in survival analysis based on the risk score
    • Grønnesby JK, Borgan O. A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal. 1996;2:315-328.
    • (1996) Lifetime Data Anal , vol.2 , pp. 315-328
    • Grønnesby, J.K.1    Borgan, O.2
  • 21
    • 0031605154 scopus 로고    scopus 로고
    • A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model
    • May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal. 1998;4:109-120.
    • (1998) Lifetime Data Anal , vol.4 , pp. 109-120
    • May, S.1    Hosmer, D.W.2
  • 31
    • 61549120401 scopus 로고    scopus 로고
    • Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: Results from PROVE IT-TIMI 22
    • Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009;29:424-430.
    • (2009) Arterioscler Thromb Vasc Biol , vol.29 , pp. 424-430
    • Ray, K.K.1    Cannon, C.P.2    Cairns, R.3    Morrow, D.A.4    Ridker, P.M.5    Braunwald, E.6
  • 32
    • 17044386913 scopus 로고    scopus 로고
    • Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study
    • Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2005;149:606-612.
    • (2005) Am Heart J , vol.149 , pp. 606-612
    • Wattanakit, K.1    Folsom, A.R.2    Chambless, L.E.3    Nieto, F.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.